Jiarong Chen

Dr. Jiarong Chen

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2014 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
GLGuixiang Liao
Guixiang Liao
ZZZhihong Zhao
Zhihong Zhao
SLShuhui Lin
Shuhui Lin
RLRong Li
Rong Li
YYYawei Yuan
Yawei Yuan
HDHaijun Deng
Haijun Deng
Robotic-assisted laparoscopy is popularly performed for colorectal disease. The objective of this meta-analysis was to compare the safety and efficacy of robotic-assisted colorectal surgery (RCS) and laparoscopic colorectal surgery (LCS) for colorectal disease based on randomized controlled trial studies.

9 September 2014 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
TZTian Zhang
Tian Zhang
QSQuanquan Sun
Quanquan Sun
TLTongxin Liu
Tongxin Liu
JCJiarong Chen
Jiarong Chen
SDShasha Du
Shasha Du
YYYawei Yuan
Yawei Yuan

6 March 2024 in Discover Oncology
Verified
Journal Article
Open access
PDF file
WPWenguang Pang
Wenguang Pang
LGLonglong Gong
Longlong Gong
WSWangpan Shi
Wangpan Shi
HZHongbo Zheng
Hongbo Zheng
MYMin Ye
Min Ye
ZWZheng Wang
Zheng Wang
Next generation sequencing (NGS) is typically used to reveal tumor gene variation feature for targeted therapy of various types of human cancers, including non-small cell lung cancer (NSCLC). Here, we report the role and potential applicable value of combining DNA and RNA sequencing in gene variation detection in NSCLC. 386 NSCLC patients with stage II-IV were enrolled and detected using NGS sequencing of DNA and RNA panels that covered all well-documented target driver genes from the Chinese Society of Clinical Oncology (CSCO). The rate of epidermal growth factor receptor (EGFR) single nucleotide variation (SNV)/indel, mesenchymal-epithelial transition factor (MET) copy number variation (CNV) and anaplastic lymphoma kinase (ALK) fusion were 52.1%, 4.1% and 6.0% in the NSCLC cohort. The landscapes of SNV/indel, CNV and gene fusion in the cohort were depicted as well. Meanwhile, we assessed detection efficacy of DNA and RNA sequencing in gene fusion. Detected number and types of gene fusion using the RNA sequencing were better than those using the DNA sequencing. Gene fusion with intergenic region was only detected by DNA sequencing and MET exon 14 skipping (METΔex14) was more easily identified by RNA sequencing. Finally, we investigated clinical correlations of SNV/indel/CNV/fusion with clinicopathologic features in the NSCLC cohort. Taken together, RNA sequencing significantly complements deficiency of DNA sequencing for gene fusion, which cooperatively presents comprehensive and reliable gene variation features and facilitate the identification of potential drug targets for NSCLC patients.

16 February 2022 in Radiotherapy and Oncology
Verified
Journal Article
Open access
JCJiarong Chen
Jiarong Chen
GSGeorges Sinclair
Georges Sinclair
HRHamoun Rozati
Hamoun Rozati
LHLaurence Hill
Laurence Hill
LPLillie Pakzad-Shahabi
Lillie Pakzad-Shahabi
MWMatt Williams
Matt Williams
To develop a novel dose-escalated volumetric modulated arc therapy (VMAT) strategy for patients with single or multiple large brain metastases which can deliver a higher dose to individual lesions for better local control (LC), and to compare dosimetry between whole brain radiotherapy (WBRT), hippocampal-sparing whole brain radiotherapy (HS-WBRT) and different VMAT-based focal radiotherapy approaches. We identified 20 patients with one to ten brain metastases and at least one lesion larger than 15 cm3 who had received WBRT as part of routine care. For each patient, we designed and evaluated five radiotherapy treatment plans, including WBRT, HS-WBRT and three VMAT dosing models. A dose of 20 Gy in 5 fractions was prescribed to the whole brain or target volumes depending on the plan, with higher doses to smaller lesions and dose-escalated inner planning target volumes (DE-iPTV) in VMAT plans, respectively. Treatment plans were evaluated using the efficiency index, mean dose and D0.1 cc to the target volumes and organs at risk. Compared with WBRT, VMAT plans achieved a significantly more efficient dose distribution in brain lesions, especially with our DE-iPTV model, while minimising the dose to the normal brain and other organs at risks (OARs) (p < 0.05). VMAT plans obtained higher doses to brain metastases and minimised doses to OARs. Dose-escalated VMAT for larger lesions allows higher radiotherapy doses to be delivered to larger lesions while maintaining safe doses to OARs.

2 June 2022 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
JCJiarong Chen
Jiarong Chen
MWMatt Williams
Matt Williams
YHYanming Huang
Yanming Huang
SSShijing Si
Shijing Si
Research on brain metastases kept innovating. We aimed to illustrate what topics the research focused on and how it varied in different periods of all the studies on brain metastases with topic modelling. We used the latent Dirichlet allocation model to analyse the titles and abstracts of 50,176 articles on brain metastases retrieved from Web of Science, Embase and MEDLINE. We further stratified the articles to find out the topic trends of different periods. Our study identified that a rising number of studies on brain metastases were published in recent decades at a higher rate than all cancer articles. Overall, the major themes focused on treatment and histopathology. Radiotherapy took over the first and third places in the top 20 topics. Since the 2010’s, increasing attention concerned about gene mutations. Targeted therapy was a popular topic of brain metastases research after 2020.

28 January 2016
Verified
Book Chapter
Closed access
PDF file
AMAndrei Mocanu
Andrei Mocanu
XFXiuyi Fan
Xiuyi Fan
FTFrancesca Toni
Francesca Toni
MWMatthew Williams
Matthew Williams
JCJiarong Chen
Jiarong Chen